NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$12.31
+0.45 (+3.79%)
Open$12.26
Previous Close$11.86
Day High$12.53
Day Low$11.90
52W High$18.48
52W Low$7.95
Volume—
Avg Volume4.07M
Market Cap1.69B
P/E Ratio—
EPS$-3.36
SectorBiotechnology
Analyst Ratings
Buy
24 analysts
Price Target
+164.1% upside
Current
$12.31
$12.31
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 84.89M | 77.82M | 223.20M |
| Net Income | -517,744,335 | -427,142,635 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -540,993,884 | -471,119,433 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |